Highest-materiality recent filing
Exagen Q2 2026: record revenue $19.9M (+16% YoY), net loss narrowed, guidance raised
Revenue $19.9M, up 16% YoY; net loss $3.2M vs $4.4M in Q2 2025, improved 28%.
Exagen reports record FY 2025 revenue of $66.6M, up 20% YoY; guides FY 2026 revenue $70-73M
Full-year 2025 revenue $66.6M (+20% YoY); Q4 2025 revenue $16.6M.
Exagen reports record 2025 revenue $66-67M, up 19-20% YoY; cash at $32M
Q4 2025 revenue $16-17M (17-24% YoY growth); full-year revenue $66-67M (19-20% YoY growth).
Exagen Q3 revenue $17.2M (+38% YoY), record; net loss $7.1M; guides FY rev $65-70M
Revenue $17.2M up 38% YoY; net loss $7.1M vs $5.0M loss last year.
Exagen Q2 revenue $17.2M (+14% YoY); net loss widens to $4.4M; FY guidance $65-70M
Revenue $17.2M, 14% YoY growth; AVISE CTD test volume +7% YoY, +14% QoQ; gross margin 60.4%.
Exagen closes $20.2M public offering at $5.25/share; net proceeds ~$18.6M
Offering of 3,350,000 shares plus full exercise of underwriter's option for 502,500 shares.
Exagen prices public offering of 3.35M shares at $5.25/share for ~$17.6M gross proceeds
3,350,000 shares priced at $5.25; gross proceeds $17.6M; net expected ~$16.2M after expenses.
Exagen Q1 revenue record $15.5M, but net loss widens to $3.8M
Revenue $15.5M (+7.5% YoY); net loss $(3.8)M vs $(3.4)M; adjusted EBITDA $(2.5)M vs $(2.0)M.
Exagen secures up to $75M term loan from Perceptive; $25M funded to retire existing debt
$25M funded at closing used to retire Innovatus debt; net proceeds ~$22.8M after costs.
Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M
Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.
Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.
Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD
Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.
Exagen posts record Q2 revenue $15.1M, raises FY2024 guidance
Record total revenue of $15.1M in Q2 2024, up from $14.1M in Q2 2023.
Exagen appoints Jeffrey Black as CFO effective Sept 1, John Aballi interim CFO
Kamal Adawi terminated as CFO and Corporate Secretary effective August 1, 2024.
Exagen appoints Jeffrey Black as CFO; Kamal Adawi steps down
Jeffrey G. Black named CFO effective Sept 1, 2024; replaces Kamal Adawi.
Exagen Q1 revenue up 28% to $14.4M; raises FY2024 guidance
Revenue $14.4M, +28.4% YoY; gross margin 59.6% vs 47.2% a year ago.
Exagen reports record FY2023 revenue of $52.5M; net loss narrows to $23.7M
Record full-year revenue $52.5M (+10% YoY); Q4 revenue $13.8M (+8% YoY)
Exagen Q3 rev $13.4M, net loss narrows to $5.4M; guides FY rev at least $50M
Revenue $13.4M vs $14.7M YoY (included $3.7M one-time Medicare); net loss $(5.4)M vs $(8.1)M.
Exagen Q2 revenue $14.1M, record AVISE CTD tests; net loss narrows to $5.0M
Revenue $14.1M, up 26% QoQ from $11.2M (Q1 2023) and up from $7.6M (Q2 2022).
Exagen Q1: record 37,312 AVISE CTD tests, revenue $11.2M (+8% YoY), net loss narrows to $7.7M
Delivered 37,312 AVISE CTD tests (+21% YoY); Q2 2023 revenue guided $10.7-11.2M.
Exagen amends loan with Innovatus: $10M prepaid, interest-only extended, revenue covenants eased
Prepaid $10M principal; prepayment fee waived.
Exagen Q4 net loss $14.4M on $5.5M goodwill impairment; Q1 revenue guidance raised to $9.2-9.7M
Record 135,210 AVISE CTD tests in 2022; 33,819 in Q4; cumulative ~750,000 since 2012 launch.
Exagen provides preliminary Q4 and FY 2022 AVISE CTD unit volumes, Q1 2023 revenue guidance
Delivered ~33,800 AVISE CTD units in Q4 2022; ~135,000 units for full year 2022.
Exagen reduces workforce by 42, estimates $750k in Q4 charges; CMO terminated
Board approved reduction in force of 42 employees, completed Dec 5, 2022, to conserve cash.
Exagen restates Q2 2022 financials for revenue errors; Q3 revenue $14.7M, guidance raised
Audit Committee determined revenue recognition errors: revenue overstated $1.4M, AR overstated $0.9M, liabilities understated $0.5M for Q2 2022.
Exagen names John Aballi CEO, succeeding Ron Rocca who resigned
John Aballi appointed CEO/President and board member effective Oct 16, 2022, replacing Ron Rocca after 11 years.
Exagen Q2 revenue $9.0M, net loss $13.3M; cuts 2022 guidance to $35-40M
AVISE CTD volume hit record 34,919 tests, up 5% YoY and 13% sequentially.
Exagen Q1 revenue $10.4M, net loss widens to $10.3M; raises FY 2022 guidance
Q1 testing revenue $10.4M (flat YoY); total revenue $10.4M vs $10.6M in Q1 2021.
Exagen adopts amended executive severance plan with enhanced CIC and non-CIC benefits
Plan covers CEO Rocca, CFO Adawi, COO Hazeltine, and CMO Debra Zack.
Exagen reports FY 2021 revenue up 15% to $48.3M; guides FY 2022 revenue $51-53M
Record 128,246 AVISE CTD tests in 2021; Q4 2021 test volume 34,147 (+21% YoY).
Exagen Q3 2021 revenue $12.3M (+14% YoY); net loss widens to $7.2M; reaffirms FY guidance
Total revenue $12.3M, up 14% YoY; AVISE CTD revenue $9.9M (+34% YoY) on 31,742 tests (+21%).
On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.
On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.
John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi
On July 25, 2024, the Company appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.
replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.
the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.
On December 6, 2023, Mark Hazeltine resigned from his position as the Company’s Chief Business Officer.
the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board.
On March 20, 2023, James L.L. Tullis informed the Board of Directors (the 'Board') of Exagen Inc. (the 'Company') that he will resign from the Board effective at the Company's 2023 annual meeting of stockholders.
On December 5, 2022, Debra Zack, M.D., Ph.D., the Company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force.
On December 5, 2022, Mark Hazeltine, the Company’s current Chief Operating Officer was appointed to serve as the Company’s Chief Business Officer.
Fortunato Ron Rocca who resigned as President and Chief Executive Officer of the Company and as a member of the Board of Directors, effective as of October 16, 2022.
Max materiality 0.85 · Median 0.60 · Most common event earnings